Browsing Tag
Non-small cell lung cancer
48 posts
Why the THIO-104 Phase 3 trial could become the most important milestone in MAIA Biotechnology’s history
Find out how MAIA Biotechnology’s ateganosine trial progress could reshape its lung cancer strategy and investor sentiment.
Can Kelun-Biotech and Merck turn sac-TMT into the first ADC plus immunotherapy standard in front-line lung cancer?
Merck needs life after Keytruda. Kelun-Biotech’s sac-TMT lung cancer data may show how the next oncology cycle takes shape.
Dizal Pharmaceutical deepens NSCLC pipeline case as DZD6008 and golidocitinib data sharpen ASCO 2026 focus
Read how Dizal’s ASCO 2026 NSCLC data for DZD6008 and golidocitinib could reshape its lung cancer pipeline strategy today!
Could oral elraglusib emerge as a combination backbone for RAS-targeted cancer therapies?
Actuate Therapeutics, Inc. is advancing oral elraglusib to target resistance biology in cancer. Discover what this means for oncology markets.
Why Lunit’s AACR 2026 showcase could reshape how investors value AI-driven precision oncology platforms like KRX: 328130
Lunit’s AACR 2026 studies reveal how its cancer AI platform is moving beyond pathology into biomarker strategy. Read what this means for KRX: 328130.
Gilead Sciences (GILD) is buying Tubulis after Arcellx and Ouro. How aggressive is this deal spree getting?
Gilead is acquiring Tubulis for up to $5 billion to expand its ADC pipeline. Read what the deal means for oncology strategy, risk, and GILD stock.
Johnson & Johnson strengthens oncology delivery strategy with EU nod for subcutaneous amivantamab
EU approves subcutaneous amivantamab for EGFR lung cancer. Discover how this could reshape oncology workflows and Johnson & Johnson’s strategy.
Saudi Arabia becomes next test for whether ANKTIVA can scale beyond U.S. oncology markets
ImmunityBio Inc. launches ANKTIVA in Saudi Arabia with pricing approval and regional partners. Find out why this move matters for global oncology strategy.
Ateganosine Phase 3 marks inflection point for MAIA Biotechnology with 2026 milestones in focus
Find out how MAIA Biotechnology’s Phase 3 ateganosine trial and 2026 milestones could reshape its regulatory path and investor narrative.
Can Partner Therapeutics’ zenocutuzumab-zbco deliver a first-line breakthrough in NRG1+ lung cancer?
Zenocutuzumab-zbco by Partner Therapeutics shows durable first-line response in NRG1+ NSCLC. Find out what the new eNRGy trial data means for patients.